CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified

A

published on Benzinga.com (subsequently unpublished) referenced a

by Adam Feuerstein indicating his opinion that Alkermes' drug candidate Bydureon would be approved. Bydureon has not been approved. Neither Alkermes' CEO nor the FDA have made any statement indicating if the drug will be approved.